Advaxis to Present at Upcoming Investor Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Advaxis (ADXS) Completes EOP2 Meeting with FDA on ADXS-HPV; Plans Phase 3 Protocol Submission
September 9, 2014 7:34 AM EDTAdvaxis (Nasdaq: ADXS) announced the completion of an End-of-Phase 2 (EOP2) Meeting with the United States Food and Drug Administration (FDA), for its lead Lm-LLO cancer immunotherapy, ADXS-HPV, for the treatment of recurrent cervical cancer in women.
The purpose of the EOP2 meeting was to discuss ADXS-HPV's preclinical data, Chemistry, Manufacturing and Controls (CMC) and... More
